capivasertib
Showing 1 - 16 of 16
Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,
Recruiting
- Premenopausal Breast Cancer
- +2 more
- Goserelin
- +3 more
-
Taipei City, TaiwanDepartment of Oncology, National Taiwan University Hospital
Feb 7, 2023
High-Risk Prostate Cancer Trial in Portland (Capivasertib, abiraterone acetate)
Not yet recruiting
- High-Risk Prostate Cancer
- Capivasertib
- abiraterone acetate
-
Portland, OregonVA Portland Health Care System, Portland, OR
Jan 17, 2023
Solid and Hematological Malignancies Trial in Berlin (Capivasertib, Rabeprazole)
Completed
- Solid and Hematological Malignancies
- Capivasertib
- Rabeprazole
-
Berlin, GermanyResearch Site
May 6, 2022
Prostate Cancer Trial in Spain, United States (Capivasertib, Enzalutamide, Abiraterone)
Completed
- Prostate Cancer
- Capivasertib
- +2 more
-
Indianapolis, Indiana
- +5 more
Jul 11, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Biopsy
- +6 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 29, 2022
Locally Advanced (Inoperable) or Metastatic Breast Cancer Trial in Worldwide (Capivasertib, Matched Capivasertib Placebo,
Recruiting
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Capivasertib
- +3 more
-
Los Angeles, California
- +76 more
Nov 25, 2022
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive
Completed
- Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
- Capivasertib
- Itraconazole
-
Berlin, GermanyResearch Site
Apr 8, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Capivasertib
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Locally Advanced (Inoperable) or Metastatic Breast Cancer Trial in Worldwide (Fulvestrant, Capivasertib, Placebo)
Active, not recruiting
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Fulvestrant
- +2 more
-
Gilbert, Arizona
- +214 more
Feb 1, 2023
Prostate Cancer Trial in Worldwide (capivasertib, docetaxel, )
Recruiting
- Prostate Cancer
- capivasertib
- +2 more
-
Phoenix, Arizona
- +203 more
Jul 27, 2022
Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in United
Recruiting
- Endometrial Undifferentiated Carcinoma
- +6 more
- Capivasertib
- +4 more
-
Birmingham, Alabama
- +741 more
Feb 2, 2023
Metastatic Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Durvalumab, Paclitaxel)
Recruiting
- Metastatic Breast Cancer
- Trastuzumab deruxtecan
- +6 more
-
Iowa City, Iowa
- +60 more
Jan 3, 2023
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation Trial in United States (Vismodegib, FAK Inhibitor GSK2256098,
Recruiting
- Intracranial Meningioma
- +2 more
- Vismodegib
- +3 more
-
Birmingham, Alabama
- +707 more
Sep 25, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022